A comparison of mortality rates for buprenorphine versus methadone treatments for opioid use disorder.
Saved in:
| Title: | A comparison of mortality rates for buprenorphine versus methadone treatments for opioid use disorder. |
|---|---|
| Authors: | Gottlieb, Daniel J. (AUTHOR), Shiner, Brian (AUTHOR), Hoyt, Jessica E. (AUTHOR), Riblet, Natalie B. (AUTHOR), Peltzman, Talya (AUTHOR), Teja, Nikhil (AUTHOR), Watts, Bradley V. (AUTHOR) |
| Source: | Acta Psychiatrica Scandinavica. Jan2023, Vol. 147 Issue 1, p6-15. 10p. 3 Charts, 1 Map. |
| Subjects: | Opioid abuse, United States. Dept. of Veterans Affairs, Death rate, Buprenorphine, Methadone hydrochloride, Mortality |
| Geographic Terms: | United States |
| Abstract: | Objective: Mortality from opioid use disorder (OUD) can be reduced for patients who receive opioid agonist treatment (OAT). In the United States (US), OATs have different requirements including nearly daily visits to a dispensing facility for methadone but weekly to monthly prescriptions for buprenorphine. Our objective was to compare mortality rates for buprenorphine and methadone treatments among a large sample of US patients with OUD. Methods: We measured all‐cause mortality, overdose mortality, and suicide mortality among US Department of Veterans Affairs patients with a diagnosis of OUD who received OAT from 2010 through 2019. We leveraged substantial and sustained regional variation in prescribing buprenorphine versus methadone as an instrumental variable (IV) and used inverse propensity of treatment weighting to balance relevant covariates across treatment groups. We compared mortality with true two‐stage IV using both probit and linear probability models, as well as a reduced form IV model, adjusting for demographics and health status. Results: Our cohort consisted of 61,997 patients with OUD who received OAT, of whom 92.7% were male with a mean age of 47.9 (SD = 14.1) years. Patients were followed for a median of 2 (IQR = 1,4) calendar years. Across regional terciles, mean methadone prescribing was 4.8%, 19.5%, and 75.1% of OAT patients. All models identified significant reductions in all‐cause and suicide mortality for buprenorphine relative to methadone. For example, predicted all‐cause mortality from the probit model was 169.7 per 10,000 person years (95% CI, 157.8, 179.6) in the lowest tercile of methadone prescribing compared with 206.1 (95% CI, 196.0, 216.3) in the highest tercile. No difference was identified for overdose mortality. Conclusion: We found significantly lower all‐cause mortality and suicide mortality rates for buprenorphine compared with methadone. Our results support the less restrictive prescribing practices for buprenorphine as OAT in the US. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Psychiatrica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Objective: Mortality from opioid use disorder (OUD) can be reduced for patients who receive opioid agonist treatment (OAT). In the United States (US), OATs have different requirements including nearly daily visits to a dispensing facility for methadone but weekly to monthly prescriptions for buprenorphine. Our objective was to compare mortality rates for buprenorphine and methadone treatments among a large sample of US patients with OUD. Methods: We measured all‐cause mortality, overdose mortality, and suicide mortality among US Department of Veterans Affairs patients with a diagnosis of OUD who received OAT from 2010 through 2019. We leveraged substantial and sustained regional variation in prescribing buprenorphine versus methadone as an instrumental variable (IV) and used inverse propensity of treatment weighting to balance relevant covariates across treatment groups. We compared mortality with true two‐stage IV using both probit and linear probability models, as well as a reduced form IV model, adjusting for demographics and health status. Results: Our cohort consisted of 61,997 patients with OUD who received OAT, of whom 92.7% were male with a mean age of 47.9 (SD = 14.1) years. Patients were followed for a median of 2 (IQR = 1,4) calendar years. Across regional terciles, mean methadone prescribing was 4.8%, 19.5%, and 75.1% of OAT patients. All models identified significant reductions in all‐cause and suicide mortality for buprenorphine relative to methadone. For example, predicted all‐cause mortality from the probit model was 169.7 per 10,000 person years (95% CI, 157.8, 179.6) in the lowest tercile of methadone prescribing compared with 206.1 (95% CI, 196.0, 216.3) in the highest tercile. No difference was identified for overdose mortality. Conclusion: We found significantly lower all‐cause mortality and suicide mortality rates for buprenorphine compared with methadone. Our results support the less restrictive prescribing practices for buprenorphine as OAT in the US. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 0001690X |
| DOI: | 10.1111/acps.13477 |
